Record turnover for KKI
Drugs firm KKI expands Galashiels plant
The news comes as KKI reports record turnover of £251 million last year, up 13% over 2015 revenues of £222m.
KKI (formerly known as ProStrakan) is a wholly-owned subsidiary of Japan-based Kyowa Hakko Kirin, the research-based life sciences company, with special strengths in biotechnologies.
KKI has acquired a 10 year lease on a 10,000 sq ft building, taking the overall size of the plant to 35,000 sq ft, capable of accommodating 200 employees.
Property adviser for the project is Eric Young & Co, with design work by design consultants, Cubit3D and project management by PMP.
Lucy Alkin-Young, KKI’s office manager, who is project managing the development, said: “We’ve been growing so fast that we were simply running out of room in our existing head office, so the expansion is being welcomed by the whole team.
“Our extended facility will provide us with a headquarters that is appropriate for an international pharmaceutical company.”
Tom Stratford (pictured), president and chief executive of KKI, said: “This development underlines our commitment to Galashiels and to Scotland as an excellent location from which to operate a truly international pharmaceutical business.
“The business is growing at pace and we are proud of what we have achieved since joining Kyowa Hakko Kirin in 2011.
“Our turnover has grown from £105m to £251m in that time, overall staff numbers have more than doubled to stand at almost 600 today and we recently filed for European approval of the first of Kyowa Hakko Kirin’s pipeline products.”